U.S. Department of Commerce 28967/34891A  Patent and Trademark Office  NFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)  Applicant Alitalo et al. Filing Date 1-19-01  Appropria  U.S. PATENT DOCUMENTS  taminer Number Date  A30 6,451,764  Negative and trademark Office  Name Class Subclass Filing Date If Appropria  FOREIGN PATENT DOCUMENTS  Taminer Document Number Date  FOREIGN PATENT DOCUMENTS  Taminer Number Document Publication Country Class Subclass Translation  Number Date Yes No.	4
NFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)  Applicant Alitalo et al.  Filing Date Group 1-19-01 1644   U.S. PATENT DOCUMENTS  taminer Number Date Name Class Subclass Filing Date If Appropria  A30 6,451,764 09/17/02 Lee, et al. 514 12  FOREIGN PATENT DOCUMENTS  taminer Number Date Class Subclass Filing Date If Appropria  Country Class Subclass Translation Date Number Date Subclass Translation Date Number Date Number Date Number Date Subclass Translation Number Date Number Date Number Date Number Number Date Number Number Number Date Number	
(Use several sheets if necessary)  Applicant Alitalo et al. Filing Date   Group   1-19-01   1644   U.S. PATENT DOCUMENTS  Taminer Number   Date   Name   Class   Subclass   Filing Date   If Appropria  A30   6,451,764   09/17/02   Lee, et al.   514   12    FOREIGN PATENT DOCUMENTS  Taminer   Document Number   Publication Date   Country   Class   Subclass   Translation   Yes   No.   N	
(Use several sheets if necessary)  Applicant Alitalo et al. Filing Date   Group   1644   U.S. PATENT DOCUMENTS  Saminer Number   Date   Name   Class   Subclass   Filing Date   If Appropria  A30   6,451,764   09/17/02   Lee, et al.   514   12    FOREIGN PATENT DOCUMENTS  Saminer   Document Number   Publication   Country   Class   Subclass   Translation   Yes   Naminer   Number	
U.S. PATENT DOCUMENTS  Taminer Number Date Date Name Class Subclass Filing Dat If Appropria  A30 6,451,764 09/17/02 Lee, et al. 514 12  FOREIGN PATENT DOCUMENTS  Taminer Number Document A30 Class Subclass Filing Date Su	
Alitalo et al.  Filing Date 1-19-01    Group   1644    Filing Date   Group   Group   1644    Filing Date   Group   1644    Filing Date   Group   Glass   Group   Group   Glass   Group   Group   Glass   Group   Group   Glass   Group   G	
U.S. PATENT DOCUMENTS  Taminer Number Date Name Class Subclass Filing Date If Appropria  A30 6,451,764 09/17/02 Lee, et al. 514 12  FOREIGN PATENT DOCUMENTS  Taminer Itials Document Number Date Country Class Subclass Translation  Translation Yes No.	
U.S. PATENT DOCUMENTS  Taminer Number	
Taminer Initials Document Number Publication Country Class Subclass Translation Yes No.	
Number Date  Yes N	
	Translation
型 7	s N
	7
	和
	- <del>Th</del>
	6
	, B
TOTAL STATES	ノクラ

OTHER DOCU	UMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
EXAMINER	DATE CONSIDERED 6-3-07
*EXAMINER: Initial if reference considered, w	hether or not citation is in conformance with MPEP 609; Draw line through
citation if not in conformance and not considere	d. Include copy of this form with next communication to applicant.

OIPE		SHEET 1 of 27
Form PTO-1449 (Modified)  APR 2 6 2002  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
INFORMATION DESCRIPTION OF THE STATEMENT	Applicant Alitalo, K. et al.	( <b>円口</b> 1002 800/290
OIPE Several sheets if necessary)	Filing Date  January 19, 2001	Group ≥ 6 8 8 1644 Ш ≈ 14

APR 2 6 2002 **U.S. PATENT DOCUMENTS** Filing Date \*Examiner Document Name Subclass Ιf Issue Class Initial Number Appropriate Date 4,543,439 09/24/85 Fracketton, Jr. et al. 435 70.21 A1 A2 4,652,639 03/24/87 536 27 Stabinsky **A3** 4,933,294 06/12/90 Waterfield et al. 436 501 A4 02/02/93 536 23.5 5,183,884 Kraus et al. **A5** 5,185,438 02/09/93 Lemischka 536 23.2 **A6** 03/30/93 Taniguchi et al. 435 252.3 5,198,359 **A7** 07/27/93 435 5,231,001 Kaplan et al. 7.21 **A8** 5,256,766 10/26/93 Coughlin 530 327 **A9** 5,270,458 12/14/93 Lemischka 536 23.5 A10 5,283,354 02/01/94 536 23.5 Lemişchka A11 5,367,057 11/22/94 Lemischka 530 350 A12 5,635,177 06/03/97 Bennett et al. 424 143.1 A13 5,643,759 07/01/97 435 70.21 Pfreundschuh, M. A14 5,693,762 12/02/97 Queen, C.L. et al. 530 387.3 A15 5,700,822 12/23/97 514 380 Hirth, K.P. et al. A 16 5,712,395 01/27/98 App, H. et al. 544 344 A17 5,747,651 05/05/98 530 -Lemischka, I.R. 387.9 A18 5,750,078 05/12/98 Shitara. K. et al. 424 133.1

EXAMINER

A19

5,763,441

**DATE CONSIDERED** 

App, H. et al.

6-3-04

514

249

\*EXAMINER:/Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

06/09/98

SHEET 2 of 27 U.S. Department of Commerce Serial No. Form PTO-1449 (Modified) Atty. Docket No. Patent and Trademark Office 28967/34891A 09/765,534 Applicant Alitalo, K. et al. INFORMATION DISCOSE STATEMENT Group Filing Date January 19, 2001 1644 (Use several sheets if necessary)

			U.S. PATE	ENT DOCUMENTS		I	
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A20	5,763,733	06/09/98	Whitlow, M. et al.	530	387.3	
	A21	5,776,427	07/07/98	Thorpe, P.E. et al.	424	1.49	
	A22	5,776,755	07/07/98	Alitalo, K. et al.	435	194	
	A23	5,798,097	08/25/98	McKenzie, I.F.C. et al.	424	181.1	
	A24	5,807,548	09/15/98	Shitara, K. et al.	424	133.1	
	A25	5,952,199	09/14/99	Davis-Smyth et al.	435	69.7	
	A26	6,011,003	01/04/00	Charnock-Jones et al.	514	2	
	A27	6,107,046	08/22/00	Alitalo, K. et al.	435	7.1	
	A28	6,130,071	10/10/00	Alitalo, K. et al.	435	69.4	
4	A29	6,331,302	12/18/01	Bennett, et al.	424	146.1	

FOREIGN PATENT DOCUMENTS									
			-				Trai	ıslation	
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No	
	B1	EP 0 325 224 A2	07/26/89	EPO					
PA	B2	WO 90/14425	11/29/90	WIPO					
	<b>B</b> 3	WO 92/13867	08/20/92	WIPO					
	B4	WO 92/14748	03/09/92	WIPO					

EXAMINER		DATE CONSIDERED ( - )-07	

Serial No. Atty. Docket No. Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office 09/765,534 28967/34891A APR 2 6 2002 Applicant Alitalo, K. et al. TRE STATEMENT INFORMATION Filing Date Group January 19, 2001 1644 (Use several sheets if necessary)

		FO	REIGN PATE	ENT DOC	UMENTS			
							Тта	nslation
*Examiner Initia/s		Document Number	Publication Date	Country	Class	Subclass	Yes	No
	B5	WO 93/14124	07/22/93	WIPO_				
	В6	WO 93/15201	08/05/93	WIPO .				00
	B7	WO 94/10202	05/11/94	WIPO			Ш	2002 1600/2
	B8	WO 95/24473	09/14/95	WIPO			_ ≥	9 2 R 16
	В9	WO 95/33772	12/14/95	WIPO			Ш	PR 2 ENTE
	B10	WO 96/39515	12/12/96	WIPO			RE	APR 2 9 2002 TECH CENTER 1600/2900
	B11	WO 97/05250	02/13/97	WIPO				1
	B12	WO 97/09427	03/13/97	WIPO				
	B13	WO 98/33917	08/06/98	WIPO				
	B14	98/07832	26/02/98	wo	6	<i>~</i>		
V	B15	99/33485	08/07/99	wo	6			

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
1	C1	Achen, M. G., et al., "Localization of Vascular Endothelial Growth Factor-D in Malignant Melanoma Suggests a Role in Tumour Angiogenesis," J. Pathol. 193(2): 147-54 (2001).
P	C2	Achen, M.G. et al., "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," Eur. J. Biochem, 267(9):2505-15 (May, 2000).

EXAMINER		1	DATE CONSIDERED 6 3-07
*EVALUED IN THE	1		de la

OIPE			SHEET	4 of 27
	S. Department of Commerce Patent and Trademark Office	Aily. Docket No. 28967/34891A	Serial No. 09/765,564	900
INFORMATION BIGGE SURE S	CTATEMENT	Applicant Alitalo, K. et al.	VEI	2002
(Use several sheets if necessary)		Filing Date January 19, 2001	Group [] 1644 ()	R 2 9
			Ш	₫ 🤇


	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C3	Achen, M.G. et al., "Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci., USA, 95(2):548-553 (January, 1998).
C4	Akagi, K., et al., "Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues," Br. J. Cancer, 83(7):887-91 (October, 2000).
C5	Andre, T., et al., "Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa," Int. J. Cancer, 86(2):174-81 (April 15, 2000).
C6	Andersson et al., "Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines," In R. F. Revoltella (ed.), Expression of Differentiated Functions in Cancer Cells. 239-245, Raven Press, New York (1982).
C7	"Angiogenesis Inhibitors in Cancer Research," Cancer Trials, at cancertrials.nci.nih.gov/news/angio/fsangio/fsangio.html (visited Jan. 24, 2001).
C8	"Angiogenesis Inhibitors in Clinical Trials," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Jan. 24, 2001).
С9	"Angiogenesis Inhibitors in Clinical Trials," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Sep. 25, 2001).
C10	"Angiogenesis Inhibitors in Clinical Trials: Expanded Trial Information," Cancer Trials, at cancertrials.nci.nih.gove/news/angio/table.html (visited Sep. 25, 2001).
C11	Aprelikova et al., "FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter," Cancer Research, 52(3):746-748 (February 1, 1992).
C12	Aujame, L. et al., "High affinity human antibodies by phage display," Human Antibodies, 8(4):155-168 (1997).
C13	Banerji, S. et al., "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan," <i>J Cell Biol.</i> 144(4):789-801 (1999).
	C4 C5 C6 C7 C8 C9 C10 C11 C12

/	
EXAMINER	DATE CONSIDERED 6-3-07
*EXAMINER: Initial if reference considered, whether or not cital citation if not in conformance and not considered. Include copy	

OIPE			SHEET	5 of 27
Form PTO-1449 (Modified) APR 2 6 2002	U.S. Department of Commerce Patent and Trademark Office	Auy. Docket No. 28967/34891A	Serial No. 09/765,534	
INFORMATION DISCHOOSURI	a cara arenaenia.	Applicant Alitalo, K. et al.	~	2800
(Use several sheets if necessor		Filing Date  January 19, 2001	1644	2002 600/29
	<del>''-'</del>			

		C S C C C C C C C C C C C C C C C C C C
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, et )
4	C14	Beckstead, J.H. et al., "Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium," Am. J. Pathol., 119(2):294-300 (May, 1985).
	C15	Benz, C. C. et al., "Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu," Breast Cancer Res Treat. 24(2):85-95 (1993).
	C16	Berridge et al., "Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIIa Glycoprotein Complex," Blood, 66(1):76-85 (July, 1985).
	C17	Bolen, J.B., "Nonreceptor Tyrosine Protein Kinases," <i>Oncogene</i> , 8:2025-2031 (1993).
	C18	Bolhuis, R.L. et al., "T cell targeting in cancer therapy," Cancer Immunology Immunotherapy, 34(1):1-8 (1991).
	C19	Borg et al., "Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase," Oncogene, 10:973-984 (1995).
	C20	Brown, L.F. et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer," Human Pathology, 26(1):86-91 (January, 1995).
	C21	Brüggemann, M. et al., "Production of human antibody repertoires in transgenic mice," Curr. Opin. Biotechnol., 8:455-458 (1997).
	C22	Brüggemann, M. et al., "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunol. Today, 17(8)</i> :391-397 (August, 1996).
	C23	Bunone, G., et al., "Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features," Am. J. Pathol, 155(6):1967-76 (December 1999).
	C24	Byrne, C. et al., "Programming Gene Expression in Developing Epidermis," Development, 120(9):2369-83 (1994).

EXAMINER	DATE CONSIDERED ( 1-07
	ion is in conformance with MPEP 609; Draw line through of this form with next communication to applicant.



1		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, et
	C25	Cantley et al., "Oncogenes and Signal Transduction," Cell, 64:281-302 (January 25, 1991).
	C26	Cao, Y., et al., "Vascular Endothelial Growth Factor C Induces Angiogenesis in Vivo," Proc. Natl. Acad. Sci. USA, 95:14389-94 (November 1998).
	C27	Carter, P. et al., "Toward the Production of Bispecific Antibody Fragments for Clinical Applications," <i>Journal of Hematotherapy</i> , 4:463-470 (1995).
	C28	Catoretti et al., "Monoclonal Antibodies Against Recombinant Parts of the Ki-67 Antigen (MIB 1 and MIB 3) Detect Proliferating Cells in Microwave-Processed Formalin-Fixed Paraffin Section," J. of Pathol., 168:357-363 (1992).
	C29	Cheng & Flanagan, "Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases," <i>Cell, 79</i> :157-168 (October 7, 1994).
	C30	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," Monoclonal Antibodies and Cancer Therapy, Alan R Liss, Inc., pp. 77-96 (1985).
	C31	Collins et al., "Continuous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture," Nature, 270:347-349 (1977).
	C32	De Gast, G.C. et al., "Clinical perspectives of bispecific antibodies in cancer," Cancer Immunol Immunother, 45:121-123 (1997).
	C33	De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science, 255:989-991 (February 21, 1992).
	C34	De Waal, R. et al., "Technical Advance: Lack of Lymphangiogenesis in Human Primary Cutaneous Melanoma," American Journal of Pathology, 150(6):1951-1957 (June, 1997).
L	C35	Devereux et al., "A Comprehensive Set of Sequence Analysis Programs for the VAX," Nucleic Acids Res., 12(1):387-395 (1984).

EXAMINER		DATE CONSIDERED 6-3-04
*EXAMINER: Initial if re	ference considered, whether or not cital	tion is in conformance with MPEP 609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

	_			
			2002	٤
Pe	TR A	IDE	MARY	\$

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant

Alitalo, K. et al.

VEC 2002

(Use several sheets if necessary)

INFORMATION DISCLOSURE STATEMENT

Filing Date

January 19, 2001

Group 5 5 1644 Ш ≈

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Dictor, M. et al., "Lymphaticovenous Differentiation in Kaposi's Sarcoma: Cellular C36 Phenotypes by Stage," American Journal of Pathology, 130(2):411-417 (February, 1988). C37 Dignam et al., "Balbiani Ring 3 in Chironomus Tentans Encodes a 185-kDa Secretory Protein Which Is Synthesized Throughout the Fourth Larval Instar," Gene, 88:133-40 (1990). C38 Dumont, D. J. et al., "Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3," Science, 282(5390):946-49 (1998). C39 Edgell et al. "Permanent Cell Line Expressing Human Factor VIII-Related Antigen Established by Hybridization," Proc. Nat'l. Acad. Sci. USA, 50:3734-3737 (June, Egeblad, M. and Jaattela, M. "Cell death induced by TNF or serum starvation is C40 independent of ErbB receptor signaling in MCF-7 breast carcinoma cells," Int J Cancer, 86(5):617-25 (2000). C41 Eggert, A., et al., "High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas," Clin. Cancer Res., 6(5):1900-8 (May 2000). C42 Eichmann et al., "Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules," Gene, 174(1):3-8 (1996). C43 Enholm, B. et al., "Vascular Endothelial Growth Factor-C, a Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," TCM, 8(7):292-297 (1998). C44 Fanger, M.W. et al., "Bispecific Antibodies," Critical Reviews in Immunology, 12(3,4):101-124 (1992). C45 Fellmer, P.T., et al., "Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas," Surgery, 126(6):1056-61 (December 1999).

	_/	1		
EXAMINER			DATE CONSIDERED	(-J-07
	$oldsymbol{N}$			

Form PTO-1449 (Modified)	APR 2 5 2002	U.S. Department of Commerce Patent and Trademark Office	1
INFORMATIO	N DASGLE SURI	E STATEMENT	
	Use several sheets if necesso		] ]

Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant Alitalo, K. et al.

Filing Date

January 19, 2001

Group
1644

700
1644

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C46	Ferrara, N. et al., "The Biology of Vascular Endothelial Growth Factor," Endocrine Reviews, 18(1):4-25 (1997).
C47	Ferrara, N. et al., "Molecular and Biological Properties of Vascular Endothelial Growth Factor," J Mol Med., 77(7):527-43. (1999).
C48	Fielder W., et al., "Expression of FLT4 and its ligand VEGF-C in Acute Myeloid Leukemia," Leukemia, 8:1234-7 (August 1997) (Abstract).
C49	Finnerty et al., "Molecular Cloning g of Murine FLT and FLT4," Oncogene, 8(11):2293-2298 (1993).
C50	Flanagan & Leder, "The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," Cell, 63:185-194 (October 5, 1990).
C51	Folkman et al., "Long-term culture of capillary endothelial cells," Proc. Nat'l Acad. Sci., USA, 76(10):5217-5221 (October, 1979).
C52	Folpe, A.L., et al., "Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3): A Marker of Vascular Tumors with Presumed Lymphatic Differentiation, Including Kaposi's Sarcoma, Kaposiform and Dabska-Type Hemangioendotheliomas, and a Subset of Angiosarcomas," Mod. Pathol, 13(2):180-185 (2000).
C53	Foote, J. et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," J. Mol. Biol., 224:487-499 (1992).
C54	Fortkamp et al., "Cloning and Expression in Escherichia coli of a Synthetic DNA for Hirudin, the Blood Coagulation Inhibitor in the Leech," DNA, 5(6):511-517 (1986).
C55	Fournier et al., "Mutation at Tyrosine Residue 1337 Abrogates Ligand-Dependent Transforming Capacity of the FLT4 Receptor," Oncogene, 11:921-931 (1995).
C56	Fournier et al., "Interaction with the Phosphotyrosine Binding Domain/Phosphotyrosine Interacting Domain of SHC Is Required for the Transforming Activity of the FLT4/VEGFR3 Receptor Tyrosine Kinase," J. Biological Chemistry, 271 (22):12956-12963 (1996).

EXAMINER (		DATE CONSIDERED / 3-64
	<i></i>	

Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
INFORMATION AISCLOSÉ DE STATEMENT	Applicant Alitalo, K. et al.	
INFORMATION DISCLOSTRE STATEMENT  (Use several sheets if necessary)	Filing Date January 19, 2001	Group 2007 6
		III a

	·	
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
y	C57	Gahmberg et al., "Membrane Glycolysation During Cell Differentiation," In L. C. Andersson, et al. (ed.), Gene Expression During Normal and Malignant Differentiation, 107-123, Academic Press, London (1985).
$\mathcal{J}$	C58	Galland et al., "Chromosomal Localization of FLT4, a Novel Receptor-Type Tyrosine Kinase Gene," Genomics, 13:475-478 (1992).
1	C59	Galland et al., "The FLT4 Gene Encodes a Transmembrane Tyrosine Kinase Related to the Vascular Endothelial Growth Factor Receptor," Oncogene, 8(11):1233-1240 (1993).
7	C60	Gasparini, G. et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, 13(3):765-782 (March, 1995).
	C61	Genbank Accession X51602 Human flt mRNA for receptor-related tyrosine kinase, deposited by Shibuya, M.
	-C62	Genbank Accession X60280 plasmid pLTRpoly, deposited by Maekelae et al.
	C63	Genbank Accession X68203 H. sapiens mRNA for FLT4, Class III receptor tyrosine kinase, deposited by Aprelikova, O.
	C64_	Genbank Accession X83287 C. coturnix Quek2 mRNA for vascular endothelial growth factor receptor, deposited by Eichmann, et al.
	C64	GenBank Accession No. AF014827, Rattus norvegicus vaseular endothelial growth factor D (VEGF-D) mRNA, deposited by Yamada, Y.
	<u>C65</u>	GenBank Accession No. A1000185, Home Sapiens mRNA for vascular endothelial growth factor-D, deposited by Achen, M.G.
•	C66	GenBank Accession No. CCY15837, Coturnix coturnix mRNA for vascular endothelial growth factor C, deposited by Eichmann, A.
	C67	GenBank Accession No. D89628, Mus musculus mRNA for vascular endothelial growth factor D, deposited by Yamada, Y.

EXAMINER	DATE CONSIDERED 6-3-47
*EXAMINER: Initial if reference considered, whether or not cita citation if not in conformance and not considered. Include copy	

Form PTO-1449 (Modified) **ÚRE STATEMENT INFORMATION** 

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

(Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
•-	C68	GenBank Accession No. MMU73620, Mus musculus VEGF-C mRNA, complete cds., deposited by Kukke, E.
		Greenberg et al., "Characterization of a New Megakaryocyte Cell Line: The Dami Cell," Blood, 72(6):1968-1977 (December, 1988).
not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers," Clin. Cancer Res., 6(11):4278-86 (November 1988)		Gunningham, S.P., et al., "The Short Form of the Alternatively Spliced flt-4 but not Its Ligand Vascular Endothelial Growth Factor C Is Related to Lymph Node Metastasis in Human Breast Cancers," Clin. Cancer Res., 6(11):4278-86 (November 2000).
	C71	Harlow et al., Antibodies: A Laboratory Manual, pp.7-25, 72-137, 141-157, 287 & 321-358 (1988).
		Hatva et al., "Expression of Endothelial Cell-Specific Receptor Tyrosine Kinases and Growth Factors in Human Brain Tumors," Am. J. Pathol., 146:368-378 (1995).
	C73	Hatva, E., et al., "Vascular Growth Factors and Receptors in Capillary Hemangioblastomas and Hemangiopericytomas," Am. J. Pathol, 148(3):763-75 (March 1996).
		Heldin et al., "Platelet-Derived Growth Factor: Mechanism of Action and Possible in Vivo Function," Cell Regulation, 1:555-566 (July, 1990).
	C75	Hemmila et al., "Europium as a Label in Time-Resolved Immunofluorometric Assays," Annal. Biochem, 137:335-343 (1984).
	C76 Hewett, P.W. et al., "Coexpression of flt-1, flt-4 and KDR in Freshly Isolated an Cultured Human Endothelial Cells," Biochemical and Biophysical Research Communications, 221:697-702 (1996).	
	C77 Hirai et al., "A Novel Putative Tyrosine Kinase Receptor Encoded by the eph Gene," Science, 238:1717-1720 (1987).	
	C78	Hirai, M. et al., "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endomatrial Carcinoma," Gynecol. Oncol. 80(2):181-8 (February, 2001).

DATE CONSIDERED 6 7 - 47	EXAMINER		DATE CONSIDERED 6 3-07
--------------------------	----------	--	------------------------

		E
orm PTO-1449 (Modified)	APR 2	5 2002 <b>\$</b>
	Arn '	
	PATE TO	

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A

Applicant

Serial No. 09/765,534

INFORMATION DISCESSURE STATEMENT

(Use several sheets if necessary)

Alitalo, K. et al.

Filing Date Group

Filing Date
January 19, 2001

Group
1644

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
1	C79	Hoogenboom, H.R., "Designing and optimizing library selection strategies for generating high-affinity antibodies," <i>TIBTECH</i> , 15:62-70 (1997).		
	C80	Hu, Jing-Shan, et al., "A Novel Regulatory Function of Proteolytically Cleaved VEGF-2 for Vascular Endothelial and Smooth Muscle Cells," <i>The FASEB Journal</i> , 11:498-504 (May 1997).		
	C81	Huang et al., "The Hematopoietic Growth Factor KL is Encoded by the SI Locus and is the Ligand of the c-kit Receptor, the Gene Product of the W Locus," Cell, 63:225-33 (October 5, 1990).		
	C82	Hunter & Greenwood, "Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity," <i>Nature</i> , 194(4827):495-496 (May 5, 1962).		
	C83	IMC-1C11, ImClone Systems Incorporated, at www.imclone.com/imc1c11.html (visited Sep. 25, 2001).		
·	C84	Irrthum, A. et al., "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.," Am J Hum Genet. 67(2):295-301 (2000).		
	C85	Jacquemier, J., et al., "Prognosis of Breast-Carcinoma Lymphagenesis Evaluated by Immunohistochemical Investigation of Vascular-Endothelial-Growth-Factor Receptor 3," Int. J. Cancer (Pred. Oncol.), 89:69-73 (2000).		
	C86	Jeltsch, "Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice," Science, 276:1423-1425 (May 30, 1997).		
	C87	Jones, A., et al., "Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis," BJU International, 86:80-86 (2000).		
	C88	Jones, P.T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 321:522-525 (May, 1986).		
+	C89	Joukov et al., "A Novel Vascular Endothelial Growth Factor, VEGF-C, is a Ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) Receptor Tyrosine Kinases," EMBO J., 15(2):290-298 (January 15, 1996).		

	<u> </u>		
EXAMINER		DATE CONSIDERED	63-07
	Y		

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date Group 1644 January 19, 2001

				_ `	
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
	<u> </u>	C90	Joukov, V. et al., "Proteolytic processing regulates receptor specificity and activity of VEGF-C," EMBO Journal, 16(13):3898-3911 (June, 1997).		
		C91	Joukov, V. et al., "A Recombinant Mutant Vascular Endothelial Growth Factor-c That Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities," J Biol Chem., 273(12):6599-602 (1998).		
		C92	Jussila, L. et al., "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against the Vascular Endothelial Growth Factor Receptor-3," Cancer Res., 58:1599-1604 (April, 1998).		
		C93	Kabashima, A. et al., "Overexpression of Vascular Endothelial Growth Factor C is Related to Lymphogenous Metasasis in Early Gastric Carcinoma," Oncology, 60(2): 146-50 (2001)		
		C94	Kadambi, A. et al., "Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A," Cancer Res. 61(6): 2404-8 (March, 2001).		
-		C95	Kaipainen et al., "Expression of the FMS-Like Tyrosine Kinase 4 Gene Becomes Restricted to Lymphatic Endothelium During Development," Proc. Nat'l Acad. Sci., USA, 92:3566-3570 (April, 1995).		
		C96	Kaipainen et al., "The Related FLT4, FLT1, and KDR Receptor Tyrosine Kinases Show Distinct Expression Patterns in Human Fetal Endothelial Cells," J. Exp. Med., 178:2077-2088 (December, 1993).		
		C97 Karkkainen, et al., "Missense Mutations Interfere With VEGFR-3 Signalling in Primary Lymphoedema," Nat Genet., 25(2):153-9 (2000).		- 	
1	<del> </del>	C98	Karkkainen, M.J., et al., "Vascular Endothelial Growth Factor Receptors in the Regulation of Angiogenesis and Lymphangiogenesis," <i>Oncogene</i> , 19(49):5598-605 (November 20, 2000).		

EXAMINER	In

DATE CONSIDERED

Form PTO-1449 (Modified) .S. Department of Commerce APR 2 6 2002 Patent and Trademark Office INFORMATION DISCLOSE (Use several sheets if necessary)

Serial No. Atty. Docket No. 28967/34891A -09/765,534 Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

		C B B C
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
f	C99	Karpanen, T. et al., "Vascular Endothelial Growth Factor C Promotes Tumor Lymphangiogenesis and Intralymphatic Tumor Growth," Cancer Res. 61(5): 1786-90 (March, 2001).
	C100	Kerstens, H. et al., "A Novel In Situ Hybridization Signal Amplification Method Based on the Deposition of Biotinylated Tyramine," Journal Histochemistry and Cytochemistry, 43(4):347-352 (1995).
	C101	Kettleborough, C.A. et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," Protein Engineering, 4(7):773-783 (1991).
	C102	Kieffer et al., "Uncoupling in the Expression of Platelet GP IIb/IIIa in Human Endothelial Cells and K562 Cells: Absence of Immunologic Crossreactivity Between Platelet GP IIb and the Vitronectin Receptor Alpha Chain," Blood, 72(4):1209-1215 (October, 1988).
	C103	Kim, K.J. et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature, 362(6423):841-844 (April, 1993).
	C104	Koeffler et al., "Acute Myelogenous Leukemia: A Human Cell Line Responsive to Colony-Stimulating Activity," Science, 200:1153-1154 (1978).
	C105	Köhler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," Nature, 256:495-497 (August 7, 1975).
	C106	Korhonen et al., "Enhanced Expression of the tie Receptor Tyrosine Kinase in Endothelial Cells During Neovascularization," Blood, 80(10):2548-2555 (November 15, 1992).
	C107	Korhonen et al., "The Mouse Tie Receptor Tyrosine Kinase Gene: Expression During Embryonic Angiogenesis," Oncogene (England), 9(2):395-403 (February, 1994).
7	C108	Korhonen, J. et al., "Endothelial-Specific Gene Expression Directed by the Tie Gene Promoter in Vivo," Blood (5):1828-35 (1995).

EXAMINER	

DATE CONSIDERED

Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. Serial No. 09/765,534 28967/34891A

Applicant

Alitalo, K. et al.

Filing Date Group January 19, 2001 1644

(Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C109	Kozbor et al., "The Production of Monoclonal Antibodies From Human Lymphocytes," <i>Immunology Today, 4(3):72-79</i> (1983).
	C110	Kubo, H., et al., "Involvement of Vascular Endothelial Growth Factor Receptor-3 in Maintenance of Integrity of Endothelial Cell Lining During Tumor Angiogenesis," Blood, 96(2):546-553 (15 July 2000).
	C111	Kukk et al., "VEGF-C Receptor Binding and Pattern of Expression with VEGFR-3 Suggests A Role in Lymphatic Vascular Development," <i>Development</i> , 122:3829-3837 (December, 1996).
C112 Kurebayashi, J., et al., "Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer," Jpn. J. Cancer Res., 90(9):977-81 (September 1999).		(VEGF) Family Members in Breast Cancer," Jpn. J. Cancer Res., 90(9):977-81
	C113	Laitinen, M. et al., "Adenovirus-mediated Gene Transfer to Lower Limb Artery of Patients With Chronic Critical Leg Ischemia," Hum Gene Ther, 9(10):1481-6 (1998).
	C114	Lauria, R. et al., "The Prognostic Value of Lymphatic and Blood Vessel Invasion in Operable Breast Cancer," Cancer, 76(10):1772-8 (1995).
	C115	Lee et al., "Vascular Endothelial Growth Factor-Related Protein: A Ligand and Specific Activator of the Tyrosine Kinase Receptor Flt4," Proc. Natl. Acad. Sci., USA, 93:1988-1992 (March, 1996).
	C116	Leu, A. J. et al., "Absence of Functional Lymphatics within a Murine Sarcoma: A Molecular and Functional Evaluation," Cancer Res, 60: 4324-7, (2000).
	C117 Lhotak et al., "Characterization of Elk, a Brain-Specific Receptor Tyrosine Kinas Mol. Cell. Biol., 11:2496-2502 (May, 1991).	
	C118	Lindberg et al. "cDNA Cloning and Characterization of eck, an Epithelial Cell Receptor Protein-Tyrosine Kinase in the eph/elk Family of Protein Kinases," Mol. Cell. Biol., 10:6316-6324 (December, 1990).
	C119	Lovgren et al., "Time-Resolved Fluorometry in Immunoassay," In: Collins W.P. (Ed.) Alternative Immunoassays, John Wiley & Sons Ltd., pp.203-217 (1985).

EXAMINER (		DATE CONSIDERED 6 1 -07
	/	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

APR 2 6 2002

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A Serial No. 09/765,534

INFORMATION DISCEOSURE STATEMENT

(Use several sheets if necessary)

Applicant Alitalo, K. et al.

Filing Date
January 19, 2001

Group 1644

A	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
C120		C120	Lozzio et al., "Human Chronic Myelogenous Leukemia Cell-Line With Positive Philadelphia Chromosome," Blood, 45(3):321-334 (March, 1975).		
Receptor: A Proliferative Factor for Primitive H		C121	Lyman et al., "Molecular Cloning of a Ligand for the flt3/flk-2 Tyrosine Kinase Receptor: A Proliferative Factor for Primitive Hematopoietic Cells," Cell, 75:1157-1167 (December 17, 1993).		
Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular		Lymboussaki, A. et al., "Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors," American Journal of Pathology, 153(2):395-403 (August, 1998).			
		C123	Makela et al., "Plasmid pLTRpoly: a Versatile High-Efficiency Mammalian Expression Vector," Gene, 118:293-294 (1992).		
		C124	Mandriota, S. J. et al., "Vascular Endothelial Growth Factor-C-Mediated Lymphangiogenesis Promotes Tumour Metastasis," EMBO J., 20(5): 672-82 (February 15, 2001).		
		C125	Marchio, S., et al., "Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells," J. Biol. Chem., 274(39):27617-22 (September 24, 1999).		
		C126	Marconcini, L., et al., "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro," Proc. Natl. Acad. Sci. USA, 96:9671-76 (August 1999).		
		C127	Martin et al., "HEL Cells: A New Human Erythroleukemia Cell Line With Spontaneous Induced Globin Expression," Science, 216:1233-1235 (1982).		
		C128	Matthews et al., "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit," Proc. Natl. Acad. Sci. USA, 88(20):9026-9030 (October, 1991).		
V	_	C129	Matthews et al., "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," Cell, 65(7):1143-1152 (June 28, 1991).		

EXAMINER	7	~	 
	1 //		

DATE CONSIDERED 6-1-07

Form PTO-1449 (Modified)

APR 2 6 2002

INFORMATION DISCLOSES

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applicant Alitale

Alitalo, K. et al.

Filing Date

January 19, 2001

Group 1644 1VE

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) C130 McCutchan et al., "Enhancement of the Infectivity of Simian Virus 40 Deoxyribonucleic Acid with Diethylaminoethyl-Dectran," J. Natl. Cancer Inst., 41:351-357 (1968). C131 Metzelaar et al., "CD63 Antigen," J. Biol. Chem., 266(5):3239-3245 (February 15, C132 Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis, Cell, 72:835-846 (March 26, 1993). C133 Minowada et al., "Brief Communication: Rosette-Forming Human Lymphoid Cell Lines: Establishment and Evidence for Origin of Thymus-Derived Lymphocytes," J. Natl. Cancer Inst., 49:891-895 (1972): Mollinedo et al., "Early and Selective Induction of Apoptosis in Human Leukemic C134 Cells By the Alkyl-Lysophospholipid ET-18-OCH<sub>3</sub>," Biochem. & Biophys. Res. Comm., 192(2):603-609 (April 30, 1993). Moriyama, M., et al., "Immunohistochemical Study of Tumour Angiogenesis in C135 Oral Squamous Cell Carcinoma," Oral Oncol., 33(5):369-74 (September 1997). C136 Moroni et al., "EGF-R Antisense RNA Blocks Expression of the Epidermal Growth Factor Receptor and Suppresses the Transforming Phenotype of a Human Carcinoma Cell Line," J. Biol. Chem., 267(5):2714-2722 (February 5, 1992). Morrison, S.L. et al., "Genetically Engineered Antibody Molecules," Advances in C137 Immunology, 44:65-92 (1989). C138 Mortimer, P. S., "The Pathophysiology of Lymphedema," Cancer, 83 (12 Suppl American):2798-802 (1998). C139 Moshakis, V. et al., "Localization of human breast-carcinoma xenografts using antibodies to carcinoembryonic antigen," Br. J. Cancer, 43:575-581 (1981). C140 Mukkala et al., "The Synthesis and Use of Activated N-Benzyl Derivatives of Diethylenetriaminetetraacetic Acids: Alternative Reagents for Labeling of Antibodies with Metal Ions," Annal. Biochem, 176:319-325 (1989).

EXAMINER	<u> </u>	

DATE CONSIDERED

6707

Form PTO-1449 (	Modified)	S. Department of Commerce	Docket No. 28967/34891A	Serial No. 09/765,534	
INFORMATION DISCLOSURE STATEMENT  OLDER AFR 2 2002  Applicant Alitalo, K. et al.  Filing Date  James 10 2001  Filing Date  James 10 2001  Jam					
`		Ise several stores if necessary)	Filing Date January 19, 2001	Group 0007 65 1644	
		R 2 2002 \$		O %	
A-	CAT.	HER DOCUMENTS (Including A	uthor, Title, Date, Pertinent	Pages, etc.)	
	C141	Mustonen et al., "Endothelial Receptor I Angiogenesis," J. Cell Biology, 129(4):8	•	ed in	
	C142	Nathanson, S.D., et al., "Microvessels" Metastases in Patients With Breast Cance	<b>-</b>	* ^ [	
	C143	Nicosia, R.F., "What Is the Role of Vaso Molecules in Tumor Angiogenesis?" Am.	and the second s	· II	
	C144 Niki, T., et al., "Expression of Vascular Endothelial Growth Factors A, B, C, and D and Their Relationships to Lymph Node Status in Lung Adenocarcinoma," Clin. Cancer Res., 6(6):2431-9 (June 2000).				
	C145	Niki, T. et al., "Expression of Vascular Blood and Lymphatic Vessels of Lung Ac (April, 2001).		- 11	
	C146	Nowell et al., "Chromosome Studies in I versus Cytopenic Disorders," Cancer, 42	-	eloproliferative	
	C147	Oelrichs et al., "NYK/FLK-1: A Putative From E10 Embryonic Neuroepithelium is Developing Embryo," Oncogene, 8(1):11	Expressed in Endothe		
	C148	Oh et al., "VEGF and VEGF-C: Specific Lymphangiogenesis in the Differentiated Developmental Biology, 188:96-109 (199)	Avian Chorioallantoic		
	C149	Ohta, Y., et al., "Increased Vascular En Endothelial Growth Factor-C and Decrea Microdissemination in the Lymph Nodes J. Thorac Cardiovasc Surg, 119(4 Pt 1):8	sed NM23 Expression in Stage 1 Non-Small	Associated with	
	€150	Ohta, Y., et al., "VEGF and VEGF type and lymphangiogenesis in human malignal 81(1):54-61 (September 1999)			

EXAMINER	M	DATE CONSIDERED 6-7-07
		er or not citation is in conformance with MPEP 609; Draw line through

		311221 10 01 27
Form PTO-1449 (Modified)  APR 2 6 2002  U.S. Department of Commerce Patent and Trademark Office	Aily. Docket No. 28967/34891A	Serial No. 09/765,534
INFORMATION DISCLOSURE STATEMENT	Applicant Alitalo, K. et al.	
(Use several sheets if necessary)	Filing Date January 19, 2001	Group 2 6 6 1644 III 8
		C) H

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
<u>-</u> .	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
	C151	O'Reilly, M.S. et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell, 79(2):315-328 (October, 1994).				
	C152	O'Reilly, M.S. et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," Cell, 88(2):277-285 (January, 1997).				
	C153	Padlan, E.A., "A Possible Procedure For Reducing The Immunogenicity Of Antibody Variable Domains While Preserving Their Ligand-Binding Properties," <i>Molecular Immunology</i> , 28(4/5):489-498 (1991).				
	C154	Pajusola et al., "FLT4 Receptor Tyrosine Kinase Contains Seven Immunoglobulin- Like Loops and is Expressed in Multiple Human Tissues and Cell Lines," Cancer Research, 52(20):5738-5743 (October 15, 1992).				
	C155	Pajusola et al., "Two Human FLT4 Receptor Tyrosine Kinase Isoforms With Distinct Carboxy Terminal Tails are Produced by Alternative Processing of Primary Transcripts," Oncogene, 8:2931-2937 (1993).				
	C156	Pajusola, "Cloning and Characterization of a New Endothelial Receptor Tyrosine Kinase FLT4 and Two Novel VEGF-Like Growth Factors VEGF-B and VEGF-C," Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Department of Biosciences, Division of Genetics, University of Helsinki, Academic Dissertation, Helsinki 1996.				
	C157	Pajusola et al., "Signalling Properties of FLT4, a Proteolytically Processed Receptor Tyrosine Kinase Related To Two VEGF Receptors," Oncogene, 9:3545-3555 (1994).				
	C158	Parker, S. H., et al., "Identification of the Sentinel Node in Patients With Breast Cancer," Radiol Clin North Am," 38(4):809-23 (2000).				
	C159	Partanen et al., "Putative Tyrosine Kinases Expressed in K-562 Human Leukemia Cells," Proc. Nat'l Acad. Sci., USA, 87(22):8913-8917 (November, 1990).				
1	,C160	Partanen et al., "A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains," Mol. Cell. Biol., 12(4):1698-1707 (April, 1992).				

EXAMINER		DATE CONSIDERED 6 1 27			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449 (Modified)

Alitalo, K. et al. Group

INFOR	MATIO	ON DISCROSURE STATEMENT			<b>~</b> ──∰
	· (U	Ise several sheets if necessary)	Filing Date January 19, 2001	Group 1644	2002
		OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent	Pages, etc.)	APR 2 9
Partanen, T.A., et al., "Lack of Lymphatic Vascular Specificity of Vascular Endothelial Growth Factor Receptor 3 in 185 Vascular Tumors," Cancer, 8 2406-12 (December 1, 1999).				iL	
<u> </u>	C162	Patent Cooperation Treaty Search Report	for PCT/US 99/23525	5	
·	C163	Paulsson, G. et al., "The Balbiani Ring 3 Repetitive Structure Split by Many Intron			
	C164	Pepper, M. S., "Lymphangiogenesis and Clinical Cancer Res., 7: 462-68 (March,		yth or Realit	y?,"
	C165 Perumov et al., "Influence of Antisense RNA's of Interleukin-1β and Interleukin-1 Receptor Antagonist on Interleukin-1β Production," J. Cell. Biochem., Supplement 16 pt B:285 (ABSTRACT J216) (1992).				
	C166	Peters et al., "Vascular Endothelial Grow Embryogenesis and Tissue Repair Sugges Blood Vessel Growth," Proc. Nat'l Acad 1993).	sts a Role in Endothelis	al Differenti	ation and
	C167	Peterson, C. and Legerski, R., "High-fred deficient Cell Lines by an Epstein-Barr V Gene, 107: 279-84, (1991).			
	C168	Pietersz et al., "Antibody Conjugates for Reviews, 129:57-80 (1992).	the Treatment of Can	cer," <i>Immun</i>	ological
	C169	Plückthun, A. et al., "New protein engin bispecific antibody fragments," Immunote			nd
	C170	Poncz et al., "Cloning and Characterizati From a Human Erythroleukemic Cell Lin	on of Platelet Factor 4	cDNA Deri	
1	C171 Rader, C. et al., "Phage Display of Combinatorial Antibody Libraries," Curr.  Opin. Biotech., 8:503-508 (1997).				

EXAMINER			DATE CONSIDERED	6-1-1
*EXAMINER: Initial it	f referen	ce considered, whether or not cita	tion is in conformance with	MPEP 600: Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
28967/34891A

Serial No.
09/765,534

Applicant
Alitalo, K. et al.

Filing Date
January 19, 2001

Serial No.
Group
1644

		मा वे			
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
1	C172	Reedijk et al., "Tyr721 Regulates Specific Binding of the CSF-1 Receptor Kinase Insert to P1 3'-Kinase SH2 Domains: a Model for SH2-Mediated Receptor-Target Interactions," EMBO J., 11(4):1365-1372 (1992).			
	C173	Relf, M. et al., "Expression of the Angiogenic Factors Vascular Endothelial Cell Growth Factor, Acidic and Basic Fibroblast Growth Factor, Tumor Growth Factor β-1, Platelet-derived Endothelial Cell Growth Factor, Placenta Growth Factor, and Pleiotrophin in Human Primary Breast Cancer and Its Relation to Angiogenesis," Cancer Research, 57:963-969 (March, 1997).			
	C174	Renner, C. et al., "Tumor Therapy by Immune Recruitment with Bispecific Antibodies," <i>Immunological Reviews, No.145</i> , pp. 179-209 (1995).			
	C175	Riechmann, L. et al., "Reshaping human antibodies for therapy," Nature, 332(6162):323-327 (March, 1988).			
	C176	Roitt, M., "Essential Immunology," Blackwell Scientific Pub., Oxford, pp.65-68 & 74 (1991).			
	C177	Rosnet et al., "Isolation and Chromosomal Localization of a Novel FMS-Like Tyrosine Kinase Gene," Oncogene, 6(9):1641-1650 (1991).			
	C178	Rosnet et al., "Murine Flt3, a Gene Encoding a Novel Tyrosine Kinase Receptor of the PDFR/CSF1R Family," Genomics, 9:380-385 (1991).			
	C179	Saaristo, A., et al., "Vascular Endothelial Growth Factor-C and its Receptor VEGFR-3 in the Nasal Mucosa and in Nasopharyngeal Tumors," Am. J. Pathology, 157(1):7-14 (July 2000).			
	C180	Sabin, F.R., "The Lymphatic System in Human Embryos, with Consideration of the Morphology of the System as a Whole," Am. J. Anat., 9(1):43-91 (1909).			
	C181	Salven, P. et al., "Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors," <i>American J. Pathology</i> , 153(1):103-108 (July, 1998).			
	C182	Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, pp. 2.60-2.70, 4.21-4.32, 7.3-7.36 (1989).			

EXAMINER	h	DATE CONSIDERED 67-07
		whether or not citation is in conformance with MPEP 609; Draw line through

SHEET 21 of 27

		SHEE	21 21 01 2	<u> </u>
Form PTO-1449 (Modified)  S. Department of Commerce Chatent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,5	34	
INFORMATION DISCLOSURES TATEMENT	Applicant Alitalo, K. et al.	(	<u> </u>	0000
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Filing Date January 19, 2001	Group 1 1644	VE 9 2002	- 6
		<u>[</u>	Д % 2	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
C183 Sato and Seiki "Regulatory mechanism of 92 kDa type IV collagenase gene				

<b>-</b>		() %
-		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C183	Sato and Seiki, "Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells," <i>Oncogene</i> , 8:395-405 (1993).
	C184	Satoh et al., "Regional Localization of the Human c-ros-1 on 6q22 and flt on 13q12," Jpn. J. Cancer Res., 78:772-775 (1987).
-	C185	Schlessinger, J., "Cell Signaling by Receptor Tyrosine Kinases," Cell, 103(2): 211-25 (October 13, 2000).
	C186	Schneider et al., "A One-step Purification of Membrane Proteins Using a High Efficiency Immunomatrix," J. Biol. Chem., 257(18):10766-10769 (September 25, 1982).
	C187	Schreiber et al., "Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition," Proc. Nat'l Acad: Sci., 82:6138-6142 (September, 1985).
	C188	Schwenk et al., "Cell Cycle Dependency of a T-Cell Marker on Lymphoblasts," Blut, 31:299-306 (1975).
	C189	Scott, P.A.E. et al., "Laboratory-Clinic Interface: Current approaches to targeting cancer using antiangiogenesis therapies," Cancer Treatment Reviews, 20:393-412 (1994).
	C190	Segal, D.M. et al., "Alternative Triggering Molecules and Single Chain Bispecific Antibodies," Journal of Hematotherapy, 4:377-382 (1995).
	C191	Segal, D.M. et al., "Targetting of Anti-Tumor Responses with Bispecific Antibodies," <i>Immunobiology</i> , 185(2-4):390-402 (August, 1992).
	C192	Sherr et al., "The c-fms Proto-Oncogene Product is Related to the Receptor for the Mononuclear Phagocyte Growth Factor, CSF-1," Cell, 41:665-676 (July, 1985).
+	C193	Shi et al., "16-Kilodalton Heparin Binding (Fibroblast) Growth Factor Type One Appears in a Stable 40-Kilodalton Complex After Receptor-Dependent Internalization," J. Biol. Chem., 266(9):5774-5779 (March 25, 1991).

EXAMINER		DATE CONSIDERED	A 2 .
*EXAMINER: Initial if	reference considered, whether or not cita	tion is in conformance with	MPEP 600: Draw line through

SHEET 22 of 27

		SHEET 2	22 of 21
Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534	
INFORMATION DECLOSION STATEMENT	Applicant Alitalo, K. et al.		02
INFORMATION DISCLOSUSE STATEMENT  (Use several sheets if necessary)	Filing Date January 19, 2001	Group > 1644	9 20
			œ

A		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C194	Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor- Type Tyrosine Kinase Gene (flt) Closely Related to the fms Family," Oncogene, 5:519-524 (1990).
( )	C195	Shibuya, M., "Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis," Advances in Cancer Research, 67:281-316 (1995).
·	C196	Shushanov, S., et al., "VEGFc and VEGFR3 Expression in Human Thyroid Pathologies," Int. J. Cancer, 86:47-52 (2000).
	C197	Skobe, M., et al., "Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi's Sarcoma," J. Invest. Dermatology, 113:1047-1053 (1999).
	C198	Skobe, M. et al., "Induction of Tumor Lymphangiogenesis by VEGF-C Promotes Breast Cancer Metastasis," Nat. Med., 7(2): 192-8 (February, 2001).
	C199	Sowter, H.M., et al., "Expression and Localization of the Vascular Endothelial Growth Factor Family in Ovarian Epithelial Tumors," Lab. Invest., 77(6):607-14 (December 1997).
	C200	Stacey et al., "SVpoly: A Versatile Mammalian Expression Vector," Nucl. Acids Res., 18(9):2829 (1990).
	C201	Stacker, S. A., "VEGF-D Promotes the Metastatic Spread of Tumor Cells Via the Lymphatics," <i>Nat. Med.</i> , 7(2): 186-91 (February, 2001).
	C202	Staunton et al., "The Arrangement of the Immunoglobulin-Like Domains of ICAM-1 and the Binding Sites for LFA-1 and Rhinovirus," Cell, 61:243-254 (April 20, 1990).
	C203	Stenman et al., "Human PDGFA Receptor Gene Maps to the Same Region on Chromosome 4 as the KIT Oncogene," Genes, Chromosomes, Cancer, 1:155-158 (1989).
X	C204	Stohrer et al., "Oncotic Pressure in Solid Tumors is Elevated," Cancer Res, 60: 4251-5, (2000).

EXAMINER		DATE CONSIDERED	(2 · 3 ~ 07
*EXAMINER: Initial if	/ eference considered, whether or not cita ance and not considered. Include copy	tion is in conformance with of this form with next com	MPEP 609; Draw line through munication to applicant.

Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534	
INFORMATION DISM OSUBESTATEMENT	Applicant Alitalo, K. et al.	. 0	
INFORMATION DISCLOSURE STATEMENT - (Use several sheets if necessary)	Filing Date January 19, 2001	Group Ш 1644	2002
			0,

		—————————————————————————————————————	: =
	<b>.</b>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
h	C205	Sundström <i>et al.</i> , "Establishment and Characterization of a Human Histiocytic Lymphoma Cell Line (U-937)," <i>Int. J. Cancer, 17:</i> 565-577 (1976).	1
	C206	Swolin et al., "On the 5q-Deletion: Clinical and Cytogenetic Observations in Ten Patients and Review of the Literature," Blood, 58:986-993 (1981).	
	C207	Taipale, J. et al., "Vascular Endothelial Growth Factor Receptor-3,"  Curr Top Microbiol Immunol., 237:85-96 (1999).	
	C208	Tang, R. F. et al., "Overexpression of Lymphangiogenesis Growth Factor VEGF-C in Human Pancreatic Cancer," Pancreas, 22(3): 285-92 (April, 2001).	
	C209	Tekmal, R.R. et al., "A Novel in Vitro and in Vivo Breast Cancer Model for Testing Inhibitors of Estrogen Biosynthesis and Its Action Using Mammary Tumor Cells With an Activated int-5/aromatase Gene," Cancer Letters, 118(1):21-28 (September, 1997).	
	C210	Tempest, P.R. et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo," BioTechnology, 9(3):266-271 (March, 1991).	
	C211	Terman et al., "Identification of a New Endothelial Cell growth Factor Receptor Tyrosine Kinase," Oncogene, 6(9):1677-1683 (1991).	
	C212	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," Biochem & Biophys. Res. Comm., 187(3):1579-1586 (September 30, 1992).	
	C213	Thompson et al., "Cloned Human Teratoma Cells Differentiate into Neuron-Like Cells and Other Cell Types in Retinoic Acid," J. Cell Sci., 72:37-64 (1984).	
	C214	Thurston, G. et al., "Leakage-resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1," Science, 286(5449):2511-4 (1999).	ľ
+	C215	Tomiyasu et al., "Long Arm Deletion of Chromosome No. 5 in a Case of Philadelphia Chromosome-Positive Chronic Myelocytic Leukemia," Cancer Genet. Cytogenet., 2:309-315 (1980).	

EXAMINER		DATE CONSIDERED 6-3-07	_
*EXAMINER: Initial if r	eference considered, whether or not cita	tion is in conformance with MPEP 609. Draw line through	

Form PTO-1449 (Modified) APR 2 5 2002 INFORMATION DISCLOSIFIÉ STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 28967/34891A

Serial No. 09/765,534

Applicant

Alitalo, K. et al.

Filing Date January 19, 2001 Group 1644

R .2

<del></del>			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
		C216	Tortora et al., "Differentiation of HL-60 Leukemia By Type I Regulatory Subunit Antisense Oligodeoxynucleotide of a cAMP-Dependent Protein Kinase," Proc. Nat'l Acad. Sci., USA, 88(5):2011-2015 (March, 1991).
		C217	Traunecker, A. et al., "Myeloma based expression system for production of large mammalian proteins," <i>Trends in BioTechnology</i> , 9(4):109-113 (April, 1991).
		C218	Tsurusaki, T., et al., "Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis," Br. J. Cancer, 801(2):309-313 (1999).
		C219	Ullrich et al., "Signal Transduction By Receptors with Tyrosine Kinase Activity," Cell, 61:203-212 (April 20, 1990).
		C220	Valtola, R., et al., "VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer," Am. J. Pathol., 154(5):1381-90 (May 1999).
		C221	van der Putte, S.C.J., "The Development of the Lymphatic System in Man," Adv. Anat. Embryol. Cell Biol., 51:3 (1975).
C222 Van Den Berghe et al., "Distinct Haematological Disorder with Deletion of L		Van Den Berghe <i>et al.</i> , "Distinct Haematological Disorder with Deletion of Long Arm of No. 5 Chromosome." <i>Nature</i> , 251:437-439 (1974).	
		C223	Van Den Berghe et al., "Transformation of Polycythemia Vera to Myelofibrosis and Late Appearance of a 5q-Chromosome Anomaly," Cancer Genet. Cytogenet., 1:157-162 (1979).
		C224	Van Hinsberg et al., "Effect of Thrombin on the Production of Plasminogen Activators and PA Inhibitor-1 by Human Foreskin Microvascular Endothelial Cells," <i>Thromb. Haemostas.</i> , 57(2):148-153 (1987).
		C225	Van Hinsberg et al., "Production of Plasminogen Activators and Inhibitors by Serially Propagated Endothelial Cells From Adult Human Blood Vessels,"  Arteriosclerosis, 7:389-400 (July/August, 1987).
	<b>)</b>	C226	Veikkola, T., et al., "Regulation of Angiogenesis Via Vascular Endothelial Growth Factor Receptors," Cancer Res., 60(2):203-12 (2000).

EXAMINER	$\sim$	DATE CONSIDERED	6-1-04
10			
*EXAMINER: Initial if referer	nce considered, whether or not citat	tion is in conformance with	MPEP 609; Draw line through
citation if not in conformance	and not considered. Include copy of	of this form with next comp	munication to applicant.

Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
INFORMATION DISELOSURA STATEMENT	Applicant Alitalo, K. et al.	۵ :
INFORMATION DISELOSURE STATEMENT  (Use several sheets if necessary)	Filing Date  January 19, 2001	Group 2007 6
		Ш ~

		O &
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C227 Verhoeyen, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536 (March, 1988).	
C228 Wang, "Signal Transduction in Human Hematopoietic Cells by Vascular Endoth Growth Factor Related Protein, a Novel Ligand for the FLT4 Receptor," Blood, 90(9):3507-3515 (November, 1997).		
·	C229	Warrington et al., "Radiation of Hybrid Map of 13 Loci on the Long Arm of Chromosome 5," Genomics, 11:701-708 (1991).
	C230	Weidner, N. et al., "Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma," J. Natl. Cancer Inst., 84(24):1875-1887 (December, 1992).
	C231	Wen, D. et al., "New Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," Cell, 69:559-572 (May 1, 1992).
	C232	Weninger, W., et al., "Expression of Vascular Endothelial Growth Factor Receptor-3 and Podoplanin Suggests a Lymphatic Endothelial Cell Origin of Kaposi's Sarcoma Tumor Cells," Lab. Invest., 79(2):243-51 (February 1999).
	C233	Whang-Peng et al., "Cytogenic Studies in Patients With Myelofibrosis and Myeloid Metaplasia," Leuk. Res., 2:41-48 (1978).
	C234	Wilkinson et al., "Expression of the Proto-Oncogene int-1 is Restricted to Specific Neural Cells in the Developing Mouse Embryo," Cell, 50:79-88 (1987).
	C235	Williams, A.F. and Barclay, A.N., "The Immunoglobin Superfamily-Domains for Cell Surface Recognition," Ann. Rev. Immunol., 6:381-405 (1988).
	C236	Williams, J.C. et al., "N-methyl-N-nitrosourea-Induced Rat Mammary Tumors. Hormonal Responsiveness but Lack of Spontaneous Metastasis," J. Nat. Cancer Inst., 66(1):147-155 (January, 1981).
h	C237	Witte et al., "Lymphangiogenesis: Mechanisms, Significance and Clinical Implications," in Regulation of Angiogenesis (eds. Goldberg, I.D. & Rosen, E. M.) 65-112 (birkhauser Verlag, Basel, Switzerland) 1997.

EXAMINER	DATE CONSIDERED (2 ) ~ 7
*EXAMINER: Initial if reference considered, whether or not cita	tion is in conformance with MPEP 609. Draw line through

Form PTO-1449 (Modified)

APR 2 6 2002

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Alitalo, K. et al.

Filing Date

January 19, 2001

Group 1644 1**VE** 9 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  C238 Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tiesus Isolamia," A westing the Setting of Tiesus Isolamia, "A westing of Tiesus Isolamia," A westing the Setting of Tiesus Isolamia, "A westing of Tiesus Isolamia," A westing the Setting of Tiesus Isolamia, "A westing the Setting of Tiesus Isolamia," A westing the Setting of Tiesus Isolamia, and th
C238 Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF
2) Promotes Angiogenesis in the Setting of Tissue Ischemia," American Journal of Pathology, Vol. 153, No.2:381-394 (August 1998).
C239 Yamaguchi et al., "Flk-1, an Flt-Related Tyrosine Kinase is an Early Marker for Endothelial Cell Precursors," Development., 118:489-498 (1993).
C240 Yarden et al., "Human Proto-Oncogene c-kit: A New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand," EMBO J., 6(11):3341-3351 (1987).
C241 Ylänne et al., "Platelet Glycoprotein IIb/IIIa Complex in Cultured Cells: Localization in Focal Adhesion Sites in Spreading HEL Cells," Blood, 72: 1478-1486 (1988).
C242 Yokoyama, Y., et al., "Prognostic Significance of Vascular Endothelial Growth Factor and Its Receptors in Endometrial Carcinoma," Gyn. Oncology 77:413-418 (2000).
C243 Yonemura, Y., et al., "Role of Vascular Endothelial Growth Factor C Expression i the Development of Lymph Node Metastasis in Gastric Cancer," Clin. Cancer Res. 5:1823-1829 (July 1999).
C244 Yonemura, Y. et al., "Lymphangiogenesis and the Vascular Endothelial Growth Factor Receptor (VEGFR)-3 in Gastric Cancer," Eur. J. Cancer, 37(7): 918-23 (May, 2001).
C245 Dias, et al., "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," Blood, 99:2179-2184 (2002)
C246 Karkkainen, et al., "Lymphatic endothelium: a new frontier of metastasis research," Nat. Cell. Biol. 4:E2-E5 (2002)
C247 Makinen, et al., "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3," Nat. Med. 7:199-205 (2001)
C248 Mattila, et al., "VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors," Int. J. Cancer 98:946-951 (2002)

**EXAMINER** 

DATE CONSIDERED

7.7.47

SHEET	27	of	27

		SHEET 27 of 27
Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/34891A	Serial No. 09/765,534
INFORMATION DISCLOSURE STATEMENT	Applicant Alitalo, K. et al.	
(Use several sheets if necessary)	Filing Date January 19, 2001	Group 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
K	C249	Siemeister, et al., "Two Independent Mechanicsms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering With Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," Cancer Res. 59:3185-91 (1999)		
	C250	Witmer, et al., "VEGFR-3 in adult angiogenesis," J. Path. 195:490-497 (2001)		

HECENTEN SOURCE IN THE SOURCE